Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Akebia Therapeutics to Present at Upcoming Investor Conferences
08:00am, Thursday, 28'th Aug 2025
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
08:00am, Thursday, 21'st Aug 2025
CAMBRIDGE, Mass. and FRANKLIN, Tenn.
Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript
07:34pm, Thursday, 07'th Aug 2025
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Erik John Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer John P
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2
09:26am, Thursday, 07'th Aug 2025
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.04 per share a year ago.
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Thursday, 07'th Aug 2025
Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million ; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to b
Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference
08:00am, Wednesday, 06'th Aug 2025
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
08:00am, Monday, 04'th Aug 2025
CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, t
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 01'st Aug 2025
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, g
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
10:41am, Friday, 01'st Aug 2025
Here is how Akebia Therapeutics (AKBA) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
08:00am, Thursday, 31'st Jul 2025
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2025, on Thu
Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Wednesday, 16'th Jul 2025
Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
10:41am, Wednesday, 16'th Jul 2025
Here is how Akebia Therapeutics (AKBA) and ResMed (RMD) have performed compared to their sector so far this year.
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
08:00am, Tuesday, 08'th Jul 2025
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, t
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 01'st Jul 2025
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
08:00am, Wednesday, 04'th Jun 2025
Akebia continues to publish important, clinically relevant data to further physicians' understanding of Vafseo® (vadadustat) Akebia continues to publish important, clinically relevant data to further
